Kura Oncology, Inc.

Equities

KURA

US50127T1097

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
20.01 ^USD	-0.25%		-2.82%	+39.15%

07-01	Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell 3000 Growth Index	CI
07-01	Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell 3000E Growth Index	CI

KURA ONCOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)

January 23, 2020 at 09:38 pm

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 23, 2020, Antonio Gualberto, M.D., Ph.D. notified Kura Oncology, Inc. (the "Company") that he will be resigning as Head of Development and Chief Medical Officer of the Company to pursue other opportunities, effective February 7, 2020.

--------------------------------------------------------------------------------

Latest news about Kura Oncology, Inc.

Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell 3000 Growth Index	06-30	CI
Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell 3000E Growth Index	06-30	CI
Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell 2000 Growth Index	06-30	CI
Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000E Value Index	06-30	CI
Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000 Value Index	06-30	CI
Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell 2500 Growth Index	06-30	CI
Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Index	06-30	CI
Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2500 Value Index	06-30	CI
Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell Small Cap Comp Value Index	06-30	CI
Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2000 Value Index	06-30	CI
Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001	05-24	CI
Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	05-15
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug	05-14	MT
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML	05-14	CI
Transcript : Kura Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Sector Update: Health Care Stocks Advance Premarket Monday	04-22	MT
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy	04-22	DJ
Kura Oncology Says Potential Leukemia Drug Ziftomenib Gets FDA Breakthrough Therapy Designation; Shares Rise Pre-Bell	04-22	MT
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	04-22	CI
Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM	03-14
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	03-06	CI
Transcript : Kura Oncology, Inc., 2023 Earnings Call, Feb 27, 2024	02-27
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI

Chart Kura Oncology, Inc.

Duration

Period

More charts

Company Profile

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Sector

Biotechnology & Medical Research

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.01 USD

Average target price

30.42 USD

Spread / Average Target

+52.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KURA ONCOLOGY, INC.	+39.15%	1.52B
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs